INTRODUCTION: Bisphosphonates, including ibandronate, are used in the prevention and treatment of osteoporosis. METHODS AND RESULTS: We report a case of suspected ibandronate-associated arrhythmia, following a single dose of ibandronate in a 55-year-old female. ECG at presentation revealed frequent ectopy and QT/QTc interval prolongation; at follow-up 9 months later the QT/QTc intervals were normalized. Proarrhythmic potential of ibandronate was assessed with a combination of in vivo and in vitro approaches in canines and canine ventricular myocytes. We observed late onset in vivo repolarization instability after ibandronate treatment. Myocytes superfused with ibandronate exhibited action potential duration (APD) prolongation and variability, increased early afterdepolarizations (EADs) and reduced Ito (P < 0.05), with no change in IKr . Ibandronate-induced APD changes and EADs were prevented by inhibition of intracellular calcium cycling. Ibandronate increased sarcoplasmic reticulum calcium load; during washout there was an increase in calcium spark frequency and spontaneous calcium waves. Computational modeling was used to examine the observed effects of ibandronate. While reductions in Ito alone had modest effects on APD, when combined with altered RyR inactivation kinetics, the model predicted effects on APD and SR Ca(2+) load consistent with observed experimental results. CONCLUSION: Ibandronate may increase the susceptibility to ventricular ectopy and arrhythmias. Collectively these data suggest that reduced Ito combined with abnormal RyR calcium handling may result in a previously unrecognized form of drug-induced proarrhythmia.
INTRODUCTION:Bisphosphonates, including ibandronate, are used in the prevention and treatment of osteoporosis. METHODS AND RESULTS: We report a case of suspected ibandronate-associated arrhythmia, following a single dose of ibandronate in a 55-year-old female. ECG at presentation revealed frequent ectopy and QT/QTc interval prolongation; at follow-up 9 months later the QT/QTc intervals were normalized. Proarrhythmic potential of ibandronate was assessed with a combination of in vivo and in vitro approaches in canines and canine ventricular myocytes. We observed late onset in vivo repolarization instability after ibandronate treatment. Myocytes superfused with ibandronate exhibited action potential duration (APD) prolongation and variability, increased early afterdepolarizations (EADs) and reduced Ito (P < 0.05), with no change in IKr . Ibandronate-induced APD changes and EADs were prevented by inhibition of intracellular calcium cycling. Ibandronate increased sarcoplasmic reticulum calcium load; during washout there was an increase in calcium spark frequency and spontaneous calcium waves. Computational modeling was used to examine the observed effects of ibandronate. While reductions in Ito alone had modest effects on APD, when combined with altered RyR inactivation kinetics, the model predicted effects on APD and SRCa(2+) load consistent with observed experimental results. CONCLUSION:Ibandronate may increase the susceptibility to ventricular ectopy and arrhythmias. Collectively these data suggest that reduced Ito combined with abnormal RyRcalcium handling may result in a previously unrecognized form of drug-induced proarrhythmia.
Authors: Douglas P Zipes; A John Camm; Martin Borggrefe; Alfred E Buxton; Bernard Chaitman; Martin Fromer; Gabriel Gregoratos; George Klein; Arthur J Moss; Robert J Myerburg; Silvia G Priori; Miguel A Quinones; Dan M Roden; Michael J Silka; Cynthia Tracy; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Elliott M Antman; Jeffrey L Anderson; Sharon A Hunt; Jonathan L Halperin; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Jean-Jacques Blanc; Andrzej Budaj; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano Journal: Circulation Date: 2006-08-25 Impact factor: 29.690
Authors: Morten B Thomsen; Avram Oros; Marieke Schoenmakers; Jurren M van Opstal; Joep N Maas; Jet D M Beekman; Marc A Vos Journal: Cardiovasc Res Date: 2006-11-23 Impact factor: 10.787
Authors: Marina Cerrone; Barbara Colombi; Massimo Santoro; Marina Raffaele di Barletta; Mario Scelsi; Laura Villani; Carlo Napolitano; Silvia G Priori Journal: Circ Res Date: 2005-05-12 Impact factor: 17.367
Authors: James E Tisdale; Matthew R Allen; Brian R Overholser; Heather A Jaynes; Richard J Kovacs Journal: J Cardiovasc Electrophysiol Date: 2015-03-31
Authors: I Aktas; C Nazikoglu; A Kepez; F U Ozkan; M Y Kaysin; P Akpinar; Z Dogan; C Ileri; S Saymaz; O Erdogan Journal: Osteoporos Int Date: 2016-06-25 Impact factor: 4.507
Authors: Ingrid M Bonilla; Victor P Long; Pedro Vargas-Pinto; Patrick Wright; Andriy Belevych; Qing Lou; Kent Mowrey; Jae Yoo; Philip F Binkley; Vadim V Fedorov; Sandor Györke; Paulus M L Janssen; Ahmet Kilic; Peter J Mohler; Cynthia A Carnes Journal: PLoS One Date: 2014-10-01 Impact factor: 3.240
Authors: Vineeta Tanwar; Matthew W Gorr; Markus Velten; Clayton M Eichenseer; Victor P Long; Ingrid M Bonilla; Vikram Shettigar; Mark T Ziolo; Jonathan P Davis; Stephen H Baine; Cynthia A Carnes; Loren E Wold Journal: J Am Heart Assoc Date: 2017-04-11 Impact factor: 5.501
Authors: Ingrid M Bonilla; Yoshinori Nishijima; Pedro Vargas-Pinto; Stephen H Baine; Arun Sridhar; Chun Li; George E Billman; Cynthia A Carnes Journal: Front Physiol Date: 2016-06-14 Impact factor: 4.566